RE:RE:Graham GrahamB wrote: DavidRosenberg wrote: Check this out
https://finance.yahoo.com/quote/RETA/
you see $RETA burn rate ???? Now what marketcap is it currently over 3 billion ... why because they have a product that markets seem worthy for potential future commercialization aveneues or Pharma buyout
biotech is weird in this way although revenues are important what's more important is having strong IP
that's the difference
I dont get the comparison.
RETA has strong and growing revenues, and beat revenues : "
Total revenues, comprising collaboration revenues, were $7.4 million compared with $1.4 million in the year-ago quarter. The top line also beat the Zacks Consensus Estimate of $1.4 million." Also have at least 2 drugs under FDA review for sppproval
HUGE has neither of these characteristics and hasn't even revealed its drug, nor even started its new , new program.
PEA didnt complete its trial, nor did the steady state trials report.
Thats the difference, as you say
Their revenues were not from drug sales though that's my point , maybe corporate dealings yet are 3 billion marketcap , but onyl have 7 million in revenues?